Bluejay Diagnostics Q3 update: SYMON-II 50% enrolled, $3.08M cash, needs $20M more by 2027

Bluejay Diagnostics, Inc.

Q3 cash $3.08M; stockholders' equity $3.69M. Raised $3.85M in April and $4.5M PIPE in October.
SYMON-II pivotal trial patient enrollment ~50% completed; sample testing expected late 2026 subject to financing.
Company expects to need at least $20M additional capital by end of FY2027 to fund operations and FDA submission.
Amended agreements with SanyoSeiko to expand manufacturing role for Symphony platform commercialization.
No revenue reported; pre-commercial stage; Symphony IL-6 test targets sepsis diagnostics, market projected at $1.8B by 2030.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.